Sara E Strollo1, Jennifer Adjemian1,2, Michael K Adjemian3, D Rebecca Prevots1. 1. 1 Epidemiology Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 2. 2 Commissioned Corps, United States Public Health Service, Rockville, Maryland; and. 3. 3 Market and Trade Economics Division, Economic Research Service, United States Department of Agriculture, Washington, DC.
Abstract
RATIONALE: State-specific case numbers and costs are critical for quantifying the burden of pulmonary nontuberculous mycobacterial disease in the United States. OBJECTIVES: To estimate and project national and state annual cases of nontuberculous mycobacterial disease and associated direct medical costs. METHODS: Available direct cost estimates of nontuberculous mycobacterial disease medical encounters were applied to nontuberculous mycobacterial disease prevalence estimates derived from Medicare beneficiary data (2003-2007). Prevalence was adjusted for International Classification of Diseases, 9th Revision, undercoding and the inclusion of persons younger than 65 years of age. U.S. Census Bureau data identified 2010 and 2014 population counts and 2012 primary insurance-type distribution. Medical costs were reported in constant 2014 dollars. Projected 2014 estimates were adjusted for population growth and assumed a previously published 8% annual growth rate of nontuberculous mycobacterial disease prevalence. MEASUREMENTS AND MAIN RESULTS: In 2010, we estimated 86,244 national cases, totaling to $815 million, of which 87% were inpatient related ($709 million) and 13% were outpatient related ($106 million). Annual state estimates varied from 48 to 12,544 cases ($503,000-$111 million), with a median of 1,208 cases ($11.5 million). Oceanic coastline states and Gulf States comprised 70% of nontuberculous mycobacterial disease cases but 60% of the U.S. population. Medical encounters among individuals aged 65 years and older ($562 million) were twofold higher than those younger than 65 years of age ($253 million). Of all costs incurred, medications comprised 76% of nontuberculous mycobacterial disease expenditures. Projected 2014 estimates resulted in 181,037 national annual cases ($1.7 billion). CONCLUSIONS: For a relatively rare disease, the financial cost of nontuberculous mycobacterial disease is substantial, particularly among older adults. Better data on disease dynamics and more recent prevalence estimates will generate more robust estimates.
RATIONALE: State-specific case numbers and costs are critical for quantifying the burden of pulmonary nontuberculous mycobacterial disease in the United States. OBJECTIVES: To estimate and project national and state annual cases of nontuberculous mycobacterial disease and associated direct medical costs. METHODS: Available direct cost estimates of nontuberculous mycobacterial disease medical encounters were applied to nontuberculous mycobacterial disease prevalence estimates derived from Medicare beneficiary data (2003-2007). Prevalence was adjusted for International Classification of Diseases, 9th Revision, undercoding and the inclusion of persons younger than 65 years of age. U.S. Census Bureau data identified 2010 and 2014 population counts and 2012 primary insurance-type distribution. Medical costs were reported in constant 2014 dollars. Projected 2014 estimates were adjusted for population growth and assumed a previously published 8% annual growth rate of nontuberculous mycobacterial disease prevalence. MEASUREMENTS AND MAIN RESULTS: In 2010, we estimated 86,244 national cases, totaling to $815 million, of which 87% were inpatient related ($709 million) and 13% were outpatient related ($106 million). Annual state estimates varied from 48 to 12,544 cases ($503,000-$111 million), with a median of 1,208 cases ($11.5 million). Oceanic coastline states and Gulf States comprised 70% of nontuberculous mycobacterial disease cases but 60% of the U.S. population. Medical encounters among individuals aged 65 years and older ($562 million) were twofold higher than those younger than 65 years of age ($253 million). Of all costs incurred, medications comprised 76% of nontuberculous mycobacterial disease expenditures. Projected 2014 estimates resulted in 181,037 national annual cases ($1.7 billion). CONCLUSIONS: For a relatively rare disease, the financial cost of nontuberculous mycobacterial disease is substantial, particularly among older adults. Better data on disease dynamics and more recent prevalence estimates will generate more robust estimates.
Authors: D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier Journal: Am J Respir Crit Care Med Date: 2010-06-10 Impact factor: 21.405
Authors: Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots Journal: Am J Respir Crit Care Med Date: 2012-02-03 Impact factor: 21.405
Authors: Kevin L Winthrop; Roger Baxter; Liyan Liu; Bentson McFarland; Donald Austin; Cara Varley; LeAnn Radcliffe; Eric Suhler; Dongsoek Choi; Lisa J Herrinton Journal: Pharmacoepidemiol Drug Saf Date: 2010-12-10 Impact factor: 2.890
Authors: Christopher Vinnard; Sarah Longworth; Alyssa Mezochow; Amee Patrawalla; Barry N Kreiswirth; Keith Hamilton Journal: Ann Am Thorac Soc Date: 2016-11
Authors: Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson Journal: Tuberculosis (Edinb) Date: 2020-02-11 Impact factor: 3.131
Authors: Javeed A Shah; Cecilia S Lindestam Arlehamn; David J Horne; Alessandro Sette; Thomas R Hawn Journal: J Infect Dis Date: 2019-08-30 Impact factor: 5.226
Authors: Caitlin Proctor; Emily Garner; Kerry A Hamilton; Nicholas J Ashbolt; Lindsay J Caverly; Joseph O Falkinham; Charles N Haas; Michele Prevost; D Rebecca Prevots; Amy Pruden; Lutgarde Raskin; Janet Stout; Sarah-Jane Haig Journal: Water Res Date: 2021-12-22 Impact factor: 11.236
Authors: Betty A Forbes; Geraldine S Hall; Melissa B Miller; Susan M Novak; Marie-Claire Rowlinson; Max Salfinger; Akos Somoskövi; David M Warshauer; Michael L Wilson Journal: Clin Microbiol Rev Date: 2018-01-31 Impact factor: 26.132